Inotiv, Inc. (NASDAQ: NOTV)

Inotiv, Inc., a prominent contract research organization, is dedicated to providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. Operating under the symbols NOTV and INVT, Inotiv is a significant player in the pharmaceutical industry.

Inotiv's primary business activities encompass two main segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment focuses on efficacy and safety evaluations, while the RMS segment offers animal research models for use in efficacy and safety evaluations. The company's operations span across various countries, providing a global reach in the pharmaceutical and medical device sectors.

The DSA segment is further divided into Discovery Services and Safety Assessment. Discovery Services include analytical method development and validation, in vivo pharmacology, exploratory pharmacokinetics and toxicology, and archiving services. Safety Assessment services consist of non-clinical toxicology and pathology, stability testing, and drug metabolism, bioanalysis, and pharmacokinetics testing. On the other hand, the RMS segment comprises Research Models, Diets and Bedding, and Research Model Services. Research Models include standard stocks and strains, immunocompromised models, disease models, and genetically-engineered models. Diets and Bedding offer laboratory animal diets, bedding, and enrichment products, while Research Model Services provide contract breeding, contract colony management, health monitoring, quarantine, cryopreservation, rederivation, and revitalization services.

Inotiv generates revenue through its diverse range of services and products. Its primary offerings include analytical method development and validation, in vivo pharmacology, exploratory pharmacokinetics and toxicology, archiving services, non-clinical toxicology and pathology, stability testing, drug metabolism, bioanalysis, and pharmacokinetics testing, contract breeding, contract colony management, health monitoring, quarantine, cryopreservation, rederivation, and revitalization services. These services cater to a wide range of clients, including biopharmaceutical companies, contract research organizations, and academic and government organizations.

Within the pharmaceutical industry, Inotiv maintains a competitive edge due to its expertise in molecular biology, analytical chemistry, and toxicology. This proficiency allows the company to provide a comprehensive suite of services to clients, from early discovery through clinical development. Furthermore, Inotiv's reputation for scientific depth and operational excellence has been built over decades, solidifying its position in the industry.

Inotiv's customers include over 2,500 companies, ranging from emerging biopharmaceutical companies to major pharmaceutical companies. The company's sales and marketing efforts are strategically focused on both pharmaceutical and medical device companies, as well as academic and government research institutions. Inotiv's commercial initiatives encompass integrated campaigns, trade events, digital and print advertising, direct communication, newsletters, social media, virtual exhibit space, and its website.

Inotiv's brand names and trade names include Discovery Services, Safety Assessment, Research Models, Diets and Bedding, and Research Model Services. These names reflect the company's diverse offerings and commitment to providing high-quality services in the pharmaceutical and medical device industries.